Intimation under Regulation 30 of SEBI (LODR)

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.6%1-day move

₹357.40

prior close

₹358.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.1+0.4-0.2+0.3+1.6+8.0+2.4+18.6+13.6+10.0+9.1+12.2+2.6—

Up moveDown movePending

AI summary

Gujarat Themis Biosyn Ltd has incorporated a new wholly owned subsidiary named 'Themis Biosyn Japan Limited' in Japan. The incorporation date was 19th May 2026, and the company received the Certificate of Registration on 20th May 2026. This is an international expansion initiative by the pharmaceutical/API manufacturer, establishing its presence in the Japanese market through a fully owned entity. The company had previously informed about this plans on 19th May 2026, and now confirms the subsidiary's formal registration.

Likely market impact

This expansion into Japan through a wholly owned subsidiary could open new revenue avenues and market reach for the company. Positive development for shareholders as it signals geographical diversification and potential business growth, though the financial impact will depend on the subsidiary's future performance.